Shots: The NDA is based on P-I/II LIBRETTO-001 study assessing selpercatinib in patients with advanced RET fusion+ NSCLC & thyroid cancer and RET-mutant MTC. The study included P-I as dose-escalation […]readmore
Tags : LOXO-292
Shots: The second P-III LIBRETTO-531 involves assessing of selpercatinib vs physician’s choice of cabozantinib or vandetanib in 400 patients in ratio (2:1) with advanced or metastatic RET-mutant MTC who have […]readmore
Shots: The companies collaborated to develop companion diagnostic utilizing Thermo Fisher’s Oncomine Dx Target Test for the identification of RET-altered NSCLC and thyroid cancer patients who may be treated with […]readmore